Catherine D. Strader, Ph.D., Joins Acorda Therapeutics Board of Directors
February 21 2017 - 7:00AM
Business Wire
Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that
Catherine D. Strader, Ph.D., has joined its board of directors,
effective February 17. Dr. Strader is currently a founding partner
at Synergy Partners R&D Solutions.
“I am delighted to welcome Dr. Strader to Acorda’s board of
directors,” said Ron Cohen, M.D., Acorda's President and CEO.
“Catherine brings decades of experience as both a drug developer
and biopharmaceutical business executive with an outstanding track
record of achievement. I expect her to add significant value to the
Board and the Company as we continue to develop our pipeline and
grow our business.”
“I am excited to be joining Acorda’s board of directors,” said
Dr. Strader. “The Company has a promising pipeline of innovative
neurological therapies. I’m looking forward to working with Ron,
the Board and the management team to help advance these
programs.”
Dr. Strader will be filling a newly-added Board seat and will be
up for re-election in 2018.
Prior to founding Synergy Partners R&D Solutions, Dr.
Strader held executive leadership positions at both Merck, where
she was Vice President and Site Head, and Schering-Plough, where
she was Executive Vice President of Discovery Research and Chief
Scientific Officer. She has guided more than 50 compounds through
drug discovery and development during her career. At Merck,
she led an external research initiative, with responsibility for
developing and implementing an integrated strategy for building
Merck's early pipeline using external sources of innovation.
At Schering-Plough, Dr. Strader had both strategic and
operational responsibility for the company’s global small molecule
and biologics discovery research portfolio, when she and her team
initiated many of the programs that currently populate the Merck
portfolio.
Dr. Strader received her B.S. in Chemistry from the University
of Virginia and her Ph.D. in Chemistry from the California
Institute of Technology. She did her postdoctoral training as a
Howard Hughes Fellow in Robert Lefkowitz’s laboratory at Duke
University and is the author of more than 150 scientific
publications.
About Acorda Therapeutics
Founded in 1995, Acorda Therapeutics is a biotechnology company
focused on developing therapies that restore function and improve
the lives of people with neurological disorders.
Acorda has an industry leading pipeline of novel neurological
therapies addressing a range of disorders, including Parkinson’s
disease, migraine and multiple sclerosis. Acorda markets three
FDA-approved therapies, including AMPYRA® (dalfampridine) Extended
Release Tablets, 10 mg.
For more information, please visit the Company’s website at:
www.acorda.com.
Forward-Looking Statement
This press release includes forward-looking statements. All
statements, other than statements of historical facts, regarding
management's expectations, beliefs, goals, plans or prospects
should be considered forward-looking. These statements are subject
to risks and uncertainties that could cause actual results to
differ materially, including: the ability to realize the benefits
anticipated from the Biotie and Civitas transactions, among other
reasons because acquired development programs are generally subject
to all the risks inherent in the drug development process and our
knowledge of the risks specifically relevant to acquired programs
generally improves over time; the ability to successfully integrate
Biotie’s operations and Civitas’ operations, respectively, into our
operations; we may need to raise additional funds to finance our
expanded operations and may not be able to do so on acceptable
terms; our ability to successfully market and sell Ampyra
(dalfampridine) Extended Release Tablets, 10 mg in the U.S.; third
party payers (including governmental agencies) may not reimburse
for the use of Ampyra or our other products at acceptable rates or
at all and may impose restrictive prior authorization requirements
that limit or block prescriptions; the risk of unfavorable results
from future studies of Ampyra or from our other research and
development programs, including CVT-301 or any other acquired or
in-licensed programs; we may not be able to complete development
of, obtain regulatory approval for, or successfully market CVT-301,
any other products under development, or the products that we will
acquire when we complete the Biotie transaction; the occurrence of
adverse safety events with our products; delays in obtaining or
failure to obtain and maintain regulatory approval of or to
successfully market Fampyra outside of the U.S. and our dependence
on our collaborator Biogen in connection therewith; competition;
failure to protect our intellectual property, to defend against the
intellectual property claims of others or to obtain third party
intellectual property licenses needed for the commercialization of
our products; and failure to comply with regulatory requirements
could result in adverse action by regulatory agencies.
These and other risks are described in greater detail in our
filings with the Securities and Exchange Commission. We may not
actually achieve the goals or plans described in our
forward-looking statements, and investors should not place undue
reliance on these statements. Forward-looking statements made in
this press release are made only as of the date hereof, and we
disclaim any intent or obligation to update any forward-looking
statements as a result of developments occurring after the date of
this press release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170221005593/en/
Acorda Therapeutics, Inc.Jeff Macdonald,
914-326-5232jmacdonald@acorda.com
Acorda Therapeutics (NASDAQ:ACOR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Acorda Therapeutics (NASDAQ:ACOR)
Historical Stock Chart
From Apr 2023 to Apr 2024